Allogeneic Epstein Barr Virus-Specific Cytotoxic T-Lymphocytes in Treating Patients With Progressive, Relapsed, or Refractory Hodgkin's Lymphoma

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically proven Hodgkin's lymphoma
• * Progressive, relapsed, or refractory disease after prior chemotherapy, radiotherapy, and/or stem cell transplantation
• * Epstein Barr virus (EBV) positive by immunohistochemical staining for LMP-1 or 2 OR the presence of EBV RNA (EBER)
• Availability of an HLA identical or haploidentical donor for cytotoxic T-lymphocytes, meeting the following criteria:
• * EBV seropositive
• * HIV negative
• * HTLV-1 negative
• * Hepatitis B surface antigen and hepatitis B core antibody IgM negative
• * Hepatitis C antibody negative
• * Must share at least 1 HLA haplotype with donor
• PATIENT CHARACTERISTICS:
• Age:
• 18 to 75
• Performance status:
• Not specified
• Life expectancy:
• At least 8 weeks
• Hematopoietic:
• Not specified
• Hepatic:
• Bilirubin less than 2.0 mg/dL
• SGOT/SGPT less than 2.5 times normal (unless liver metastases are present)
• * If there is liver involvement by disease, an obvious relationship between SGOT/SGPT and disease activity is required
• No hepatic dysfunction causing moribundity
• Renal:
• Creatinine clearance greater than 50 mL/min
• No renal dysfunction causing moribundity
• Cardiovascular:
• No cardiac dysfunction causing moribundity
• Pulmonary:
• No pulmonary dysfunction causing moribundity
• Other:
• No neurologic dysfunction causing moribundity
• No history of severe transfusion reactions with blood products (including fetal calf serum)
• Not pregnant
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• See Disease Characteristics
• Chemotherapy:
• See Disease Characteristics
• No concurrent antimetabolites
• Endocrine therapy:
• Not specified
• Radiotherapy:
• See Disease Characteristics
• Surgery:
• Not specified